Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.19507 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von L Gargiulo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
ORCID-Profile: L Gargiulo, L Ibba, A Costanzo
Zitieren
APA
Gargiulo, L., Ibba, L., Piscazzi, F., Alfano, A., Cascio Ingurgio, R., Valenti, M., Costanzo, A., & Narcisi, A. (2024). Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19507
Vancouver
Gargiulo L, Ibba L, Piscazzi F, Alfano A, Cascio Ingurgio R, Valenti M, et al. Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19507
BibTeX
@article{Gargiulo2024,
author = {Gargiulo, L and Ibba, L and Piscazzi, F and Alfano, A and Cascio Ingurgio, R and Valenti, M and Costanzo, A and Narcisi, A},
title = {Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.19507}
}
EUVIMED